



## Quick Reference Guide - Neuromodulation Outpatient Hospital 2025

The following are the 2025 Medicare coding and national payment rates for Peripheral Nerve Stimulation (PNS) procedures performed in the outpatient hospital setting. Comprehensive Ambulatory Payment Classifications (C-APCs) are effective for services performed in an Outpatient Hospital. A C-APC is a single all-inclusive payment for a primary device dependent service and all adjunct services provided to support the delivery of the primary service.

**For reimbursement support, please contact: [reimbursement@nalumed.com](mailto:reimbursement@nalumed.com) or 1-800-618-3402**

CPT <sup>o1</sup>	Description	APC <sup>2</sup>	Status Indicator <sup>3</sup>	National Base Payment <sup>4</sup>
<b>Leads &amp; Pulse Generator Placement Codes</b>				
64555	Percutaneous implantation of neurostimulator electrode array: peripheral nerve (excludes sacral nerve)	5462	J1	\$6,563
64590	<u>Insertion or Replacement</u> of peripheral, sacral or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver	5464	J1	\$21,444
<b>Revision/Removal of Leads and Pulse Generators</b>				
64585	<u>Revision or removal</u> of peripheral neurostimulator electrode array	5461	J1	\$3,439
64595	<u>Revision or removal</u> of peripheral, sacral or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array	5461	J1	\$3,439
HCPCS Code <sup>5</sup>	Descriptor			
C1778	Lead, neurostimulator (implantable)			
C1897	Lead, neurostimulator test kit (implantable)			
C1767	Generator, neurostimulator (implantable), nonrechargeable			
C1816	Receiver and/or transmitted, neurostimulator (implantable)			
C1883	Adapter/ extension, pacing lead or neurostimulator lead (implantable)			

Hospital Outpatient Modifiers

- 50 Bilateral Procedure
- 52 Reduced Services
- 58 Staged or Related Procedure by the Same Physician During the Postoperative Period
- 73 Discontinued Procedure Prior to the Administration of Anesthesia
- 74 Discontinued Procedure After the Administration of Anesthesia

## Medicare National Coverage Determination (NCD)

In the case of spinal cord stimulation, Medicare has a longstanding National Coverage Determination (NCD) for electrical nerve stimulators (160.7) that includes specific criteria for coverage, which are as follows:

- The implantation of the stimulator is used only as a last resort (if not a last resort) for patients with chronic intractable pain;
- With respect to item A, other treatment modalities (pharmacological, surgical, physical, or psychological therapies) have been tried and did not prove satisfactory, or are judged to be unsuitable or contraindicated for the given patient;
- Patients have undergone careful screening, evaluation, and diagnosis by a multidisciplinary team prior to implantation. (Such screening must include psychological, as well as physical evaluation);
- All the facilities, equipment, and professional and support personnel required for the proper diagnosis, treatment training, and follow up of the patient (including that required to satisfy item c) must be available; and
- Demonstration of pain relief with a temporarily implanted electrode precedes permanent implantation.

Medical National Coverage Determination for Electrical Nerve Stimulators (160.7) can be found at:  
<https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=240>

## Medicare Local Coverage Determinations

In addition to NCD criteria, some Medicare Administrative Contractors (MACs) may require additional SCS coverage criteria called local coverage determinations (LCDs). Please check with your local contractor. In absence of an LCD, Medicare contractors will follow the NCD. Please note that LCD jurisdiction is subject to change.

MAC	Jurisdiction	States Covered	Web Link	LCD Number* Article Number <sup>†</sup>
Noridian Healthcare Solutions <sup>‡</sup>	J-E	California, Hawaii, Nevada, American Samoa, Guam, Northern Mariana Islands	<a href="https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?lcdid=34328">https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?lcdid=34328</a>	L34328
			<a href="https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleid=55530">https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleid=55530</a>	A55530
Noridian Healthcare Solutions <sup>‡</sup>	J-F	Alaska, Arizona, Idaho, Montana, North Dakota, Oregon, South Dakota, Utah, Washington, Wyoming	<a href="https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?lcdid=37360">https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?lcdid=37360</a>	L37360
			<a href="https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleid=55531">https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleid=55531</a>	A55531

\*LCDs include Coverage Indications, Limitations, and/or Medical Necessity.

<sup>†</sup>Articles include CPT codes, ICD-10 Diagnosis Codes, and Utilization Guidelines.

<sup>‡</sup>No other MACs have published a LCD for Peripheral Nerve Stimulation.

## INDICATIONS FOR USE

### Spinal Cord Stimulation (SCS)

This system is indicated as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach for chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain. The trial devices are solely used for trial stimulation (no longer than 30 days) to determine efficacy before recommendation for a permanent (long term) device.

### Peripheral Nerve Stimulation (PNS)

This system is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach. The Nalu Neurostimulation System for PNS is not intended to treat pain in the craniofacial region. The trial devices are solely used for trial stimulation (no longer than 30 days) to determine efficacy before recommendation for a permanent (long term) device.

Disclaimer: Health economic and reimbursement information provided by Nalu Medical, Inc. is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Nalu Medical encourages providers to submit accurate and appropriate claims for services. It is always the provider's responsibility to determine medical necessity, the proper site for delivery of any service and to submit appropriate codes, charges, and modifiers for services that are rendered. Nalu Medical recommends that you consult with your payers, reimbursement specialists and/or legal counsel regarding coding, coverage, and reimbursement matters. Nalu Medical does not promote the use of its products outside their FDA-approved label. Information included herein is current as of January 1, 2024 but is subject to change without notice. Rates for services are effective January 1, 2025.

1. CPT Copyright 2024 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association. Applicable FARS/DFARS. Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
2. FY 2025 CMS OPPS Final Rule, [CMS-1809-FC], Addendum B.
3. Hospital Outpatient Status Indicators:  
J1: Hospital Part B services paid through a comprehensive APC (only one payment will be made for the episode of care).
4. Code of Federal Regulations, §512.250, Determination of national base rates. URL:  
<https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-H/part-512/subpart-B/subject-group-ECFR388d9ab0bb970d0/section-512.250>
5. C-codes are required for billing Medicare outpatient procedures in conjunction with the applicable CPT codes but are not separately payable by Medicare.
6. Medicare National Coverage Determination (NCD) for Electrical Nerve Stimulators (160.7) Publication Number 100-3, Manual Section Number 160.7, Benefit Category; Prosthetic Devices NCD.